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The μ opioid receptor (μOR) is a G protein-coupled receptor (GPCR) that is the target of most 
clinically and recreationally used opioids. The induced positive effects of analgesia and euphoria 
are mediated by μOR signaling through the adenylyl cyclase-inhibiting heterotrimeric G protein 
Gi. We present the 3.5-Å resolution cryo-electron microscopy (cryo-EM) structure of the μOR 
bound to the agonist peptide DAMGO and nucleotide-free Gi. DAMGO occupies the morphinan 
ligand pocket, with its N-terminus interacting with conserved receptor residues while its C-
terminus engages regions important for opioid ligand selectivity. Comparison of the μOR-Gi 
complex to previously determined structures of other GPCRs bound to the stimulatory G protein 
Gs reveals differences in the movement of transmembrane receptor helix 6 and in the interactions 
between the G protein α subunit and the receptor core. Together, these results shed light into the 
structural features that contribute to the Gi protein coupling specificity of the μOR.
The μOR is the primary target of morphine and many clinically used opioid analgesics1. 
Opioid binding to the μOR leads to clinically desired analgesic and antitussive actions but 
also important negative side effects including addiction and potentially lethal respiratory 
suppression. Opioids have become the most prescribed class of medication in the United 
States2, leading to a national epidemic of addiction and an unprecedented level of drug 
overdose deaths.
Like other GPCRs, the μOR achieves many of its physiological actions by stimulating 
signaling via a heterotrimeric G protein. While other GPCRs have been shown to signal 
through more than one G protein subtype, the μOR signals almost exclusively through the 
adenylyl-cyclase inhibitory family of G proteins (Gi/o)3. The analgesic activity of opioids is 
driven by G protein activation4, but activated μOR can also interact with β-arrestins, whose 
recruitment has been associated with the respiratory depression induced by many opioids5,6. 
Recently developed molecules that favor Gi signaling over arrestin recruitment display 
analgesic efficacy with reduced side effects, suggesting that different signaling pathways can 
be selectively targeted to yield unique physiological outcomes7,8. Though a framework for 
GPCR interactions with the stimulatory G protein Gs has recently been enabled by X-ray 
crystallography9 and cryo-electron microscopy (cryo-EM)10,11, the structural basis for 
GPCR signaling through other G protein subtypes remains undefined. To better understand 
the mechanism of selective activation of Gi by the μOR, we sought to determine the structure 
of the μOR-Gi complex.
3.5-Å cryo-EM map of a μOR-Gi complex
DAMGO (H-Tyr-D-Ala-Gly-N-MePhe-Gly-OH) is a μOR-selective synthetic analog of the 
natural peptide agonist enkephalin. DAMGO-bound μOR was incubated with Gi1 
heterotrimer and the complex was treated with the nucleotide hydrolase apyrase to remove 
GDP. The resulting nucleotide-free complex was further stabilized by a single-chain variable 
fragment (scFv16) that binds to heterotrimeric Gi (Extended Data Figure 1) and prevents 
GTPγS mediated dissociation of nucleotide-free complexes. We applied single-particle 
cryo-EM to initially obtain a three-dimensional map of the μOR-DAMGO-Gi-scFv16 
complex at an indicated nominal resolution of 3.6 Å (Extended Data Fig. 2–3, Extended 
Data Table 1). Notably, scFv16 binds a composite interface comprised of the αN helix of 
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Gαi and the β propeller of Gβ, a site that is more than 20 Å distal to the μOR-Gαi interface 
and does not perturb the interface between Gα and Gβ subunits (Extended Data Figure 1). 
Subtraction of the scFv16 signal from raw particle images led to an improved map with an 
indicated global resolution of 3.5 Å. This map displayed enhanced features particularly in 
the receptor transmembrane core (Extended Data Figures 2, 3, 4), enabling the high 
resolution visualization of the μOR-Gi interface and ligand binding. Accordingly, we 
employed this improved 3.5-Å map to examine interactions between μOR and DAMGO, and 
between μOR and Gi (Fig. 1a, b).
Activation of μOR by a peptide agonist
We previously determined the active-state crystal structure of μOR bound to the morphinan 
agonist BU72 and an active-state stabilizing nanobody (Nb39) at a resolution of 2.2 Å12. 
Like other small molecule morphinans, BU72 is rigidified by a complex ring system, in 
contrast to flexible opioid peptides like DAMGO that have multiple rotatable bonds. The 
cryo-EM map includes well-defined features for most amino acids forming the orthosteric 
binding pocket (Extended Data Fig. 4a). Despite differences in agonist structure, the 
conformation of the active-state binding pocket and the orientation of the amino acids that 
interact with the agonist are highly similar for the μOR bound to BU72 or DAMGO (Fig. 
1c), suggesting that the μOR recognizes structurally distinct agonists in a stereotypic 
manner.
Although DAMGO is a flexible ligand, we observe density for the entire peptide bound to 
the receptor (Fig. 1a, Extended Data Fig. 3, 4). The DAMGO N-terminus occupies a similar 
position in the binding pocket as BU72. In contrast, the C-terminus of DAMGO extends ~8 
Å further towards the extracellular loops compared to BU72 (Fig. 1d, e). To identify stable 
atomic-level interactions between DAMGO and the binding pocket, we performed molecular 
(MD) dynamics simulations. In over 1μs of simulation, DAMGO remained close to its 
initially modeled pose, with the amino-terminal portion largely remaining confined to the 
experimentally determined EM density (Fig. 1f, Extended Data Fig 5). The DAMGO N-
terminus maintained a persistent salt bridge with D1473.32, a feature previously observed in 
structures of morphinans bound to opioid receptors (Fig. 1e; superscripts indicate 
Ballesteros-Weinstein numbering for GPCRs13). The same amine group also often formed a 
hydrogen bond with Y3267.43. More generally, the amino-terminal Tyr of DAMGO overlaps 
the phenolic group of other small molecule opioids characterized previously by X-ray 
crystallography14–17.
MD simulations also revealed a water-mediated hydrogen bonding network that closely 
overlaps with the water network observed in the high-resolution crystal structure of μOR12 
(Extended Data Fig. 6). In particular, the simulations revealed a stable, water-mediated 
interaction formed between the DAMGO phenol and H2976.52. Though the crystal structure 
of the μOR bound to BU-72 shows two water molecules bridging the DAMGO phenol and 
H2976.52, simulations of μOR bound to DAMGO and other phenolic ligands8,12 suggest that 
one of these waters rapidly dissociates and that a single water is required for stable ligand 
binding. This interaction is a hallmark of opioid recognition that has been observed for 
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morphinans in complex with the μOR12,14 as well as other small molecule and peptide-
mimetic agonists for the homologous δ and κ opioid receptors (κOR)15,16,18.
DAMGO is more than 500-fold selective for the μOR over the δOR and κOR19. As 
elucidated in prior structures, ligand interactions with the extracellular loops encode ligand 
subtype specificity among closely related opioid receptors15. Indeed, DAMGO selectivity 
for μOR over δOR has been shown to result from residues in ECL1 while selectivity over 
κOR results from differences in ECL320. The map density for the carboxy-terminal residues 
of DAMGO is slightly weaker than for the amino-terminus, consistent with increased 
mobility of this region in simulations (Fig. 1f, Extended Data Fig 5). In our model, the 
DAMGO N-Me-Phe side chain occupies a conserved hydrophobic pocket near ECL1 and the 
Gly-OH group folds back over the ligand (Fig. 1e). This model is consistent with the high 
affinity μOR binding of cyclized enkephalins that bridge the +2 and +5 positions of the 
peptide21.
Structure of Gi-Stabilized Active μOR
The overall structure of Gi-bound μOR is similar to the active conformation of the BU72-
bound μOR stabilized by Nb39 (root mean square deviation of 1 Å)12 with a predominant 
outward displacement of TM6 from the heptahelical bundle relative to the inactive state (Fig. 
2a, b). A number of highly conserved residues in the GPCR family have been shown to be 
important for receptor activation, including the D3.49R3.50Y3.51, the N7.49P7.50xxY7.53, and 
conserved core triad (I3.40, P5.50, and F6.44) motifs. The conformation of each of these 
regions in the μOR-Gi complex is virtually identical to the active state observed in complex 
with Nb39 (Fig. 2c). The structural similarity of μOR between Nb39 and Gi-coupled states 
indicate that these changes underlie ligand-mediated activation and are not specific to a 
particular intracellular binder. Indeed, Nb39 and Gi promote a similar increase in agonist 
affinity12, which supports a common mechanism of allosteric communication between the 
intracellular G protein coupling domain and the ligand binding pocket12.
Two differences between Nb39 and Gi stabilized active-states of μOR are particularly 
notable. First, compared with the nanobody-stabilized active-state μOR, TM6 in the μOR-Gi 
complex is further displaced by 3 Å towards TM7 (Fig. 2b). Second, the conformation of 
intracellular loop 3 (ICL3) is different in the two structures (Fig. 2a). It is likely that the 
specific ICL3 conformation of μOR stabilized by Nb39 reflects interactions that are unique 
to the nanobody rather than a general feature of receptor activation prior to G protein 
coupling. A similar difference in ICL3 conformation was previously observed for the β2-
adrenergic receptor (β2AR) between nanobody (Nb80)22 and Gs-coupled states. The 
comparison of the G protein bound states of both receptors shows that the β2AR TM6 is 
displaced outward by another 9 Å compared to the μOR (Fig. 2d).
Structural Changes in Gi
The quality of the cryo-EM map enabled accurate modeling of Gi in its nucleotide-free state, 
providing insight into the structural changes that underlie nucleotide release. The changes 
we observe are similar to those observed in nucleotide-free Gs in complex with other 
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GPCRs. The most striking difference between the GDP bound23 and nucleotide free 
heterotrimer in complex with μOR involves the separation of the α-helical domain (AHD) 
from the Ras-like domain in the alpha subunit of Gi (Gαi) (Fig. 3a). Due to its relative 
flexibility, we excluded the AHD density from the high-resolution map refinement. The 
dynamic character of the AHD has been observed previously by spectroscopic and structural 
studies in complexes between receptors and both Gs9–11 and Gi24,25. Displacement of the 
AHD disrupts several contacts with GDP and is necessary, but not sufficient for nucleotide 
release, a process that involves breaking additional contacts with the Ras domain24.
Gi coupling to the μOR also involves a 6-Å translation as well as a 60° rotation of the Gαi 
α5 helix into the receptor core (Fig. 3b). This movement has been shown to be essential for 
nucleotide release in Gi24. In particular, the motion of α5 leads to a change in the position of 
the β6-α5 loop containing the conserved TCAT motif that forms direct interactions with the 
guanine base of GDP. This displacement disrupts key contacts between the G protein and 
nucleotide. Furthermore, the observed translation and rotation of the α5 helix requires the 
displacement of the fully conserved F336 away from the hydrophobic pocket formed by 
residues in the β2/β3 strands and the α1 helix26 (Fig. 3b). Movement of the α5 helix is also 
propagated to the phosphate binding P-loop connecting the β1 strand and the α1 helix by 
disruption of a hydrophobic network between the α1 and α5 helices (Fig. 3b–d). 
Correspondingly, upon transition of Gi to the nucleotide-free state, we observe a 4-Å shift of 
α1 towards the α5 helix in Gi whereby the hydrophobic contacts are replaced by polar 
interactions with the β6-α5 loop as it is released from its guanine binding position (Fig. 3c, 
d). These changes contrast those observed in structures of Gs-coupled complexes, in which 
α1 not only becomes more unstructured, but also tends to lose interactions with the α5 helix 
(Fig. 3e). Our structure is consistent with previous studies suggesting that engagement of a 
GPCR with the α5 helix and αN- β1 loop leads to concerted changes in the α1 helix and P 
loop that destabilize contacts with the guanine nucleotide leading to its release27.
Structural insights into Gi coupling specificity of the μOR
Although the μOR couples exclusively to Gi/o3, many GPCRs can couple to multiple G 
protein subtypes; a well-studied example is the β2AR, which couples to both Gs and Gi/o. 
Prior sequence-level analyses have failed to identify a linear GPCR epitope that determines 
G protein coupling specificity, suggesting that it is likely determined by a more complex 
three-dimensional network of interactions. Globally, the structure of the μOR-Gi complex is 
similar to the β2AR-Gs, likely reflecting a similarity in the conformation of nucleotide-free 
states of Family A GPCR-G protein complexes. The primary interaction sites in both 
complexes occur between ICL2, ICL3 and TMs 3,5, and 6 on the receptor and the αN, αN- 
β1 loop, and α5 helix on the Gα subunit of the G protein (Fig. 4). The most striking 
difference between the β2AR-Gs and μOR-Gi complex is in the relative position of the α5 
helix of both G proteins, as well as the corresponding shift in the position of TM6 of the 
receptor. The α5 helix of Gαi is rotated ~21° relative to the α5 helix of Gαs, leading to a 5 
Å displacement of the extreme C-terminus of the Gαi helix α5 toward TM7 of the μOR (Fig. 
4a). This difference in α5 positioning is associated with a smaller outward displacement of 
the μOR TM6. The C-terminal residues of α5 that interact with TMs 5 and 6 of the receptor 
are bulkier in Gs than in Gi, with Y and E compared to C and G at positions −4 and −3 from 
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the C-terminus, respectively. Accordingly, substitution of these two amino acids of Gs into 
Gi would lead to steric clashes with TM3 and the TM7-Helix 8 loop (Extended Data Fig. 7). 
In the Gs-coupled Family B calcitonin11 and GLP-110 receptors, G protein coupling is 
associated with a large kink of TM6 at the conserved PxxG motif, which produces an even 
larger outward displacement of TM6 than what observed in the β2AR-Gs complex.
Surprisingly, the structure of μOR-Gi shows substantial similarity to an active-state structure 
of the visual pigment rhodopsin (Meta II) in complex with a modified peptide derived from 
the 11 C-terminal residues of the α subunit of the visual G protein transducin (GαtCT2) 
(Extended Data Fig. 8)28. Despite the lack of the remainder of the heterotrimeric G protein 
in the MetaII- GαtCT2 structure, the conformation of TM6 of MetaII is highly similar to 
that of the μOR, while the location of the GαtCT2 peptide is almost identical to the C-
terminus of Gi in complex with μOR. This finding is consistent with observations that 
substitution of the last five amino acids of the Gα α5 helix is sufficient to change G protein 
coupling specificity29.
In Extended Data Table 2, we list amino acids in the μOR that interact with the cytoplasmic 
surface of Gi. The μOR ICL2 primarily forms interactions with the αN and α5 helices of 
Gαi, including a key ionic interaction between the μOR D17734.55 [G Protein Coupled 
Receptor Data Base (GPCRDB) numbering30] in ICL2 and R32 in the αN- β1 loop of Gαi 
(Fig. 4b). Although D34.55 in ICL2 is conserved in all opioid receptors with available 
sequences (GPCRDB31), it is variable in most other Gi coupled receptors. Another notable 
interaction involves R17934.57 in μOR ICL2, which simultaneously coordinates the highly 
conserved D1643.49 in the DRY motif and potentially forms an additional interaction with 
D350 in the Gαi α5 helix (−5 position) (Fig. 4b). This arginine is essential for μOR induced 
Gi signaling, as the polymorphic variant R179C abolishes signaling in vitro32 and leads to 
insensitivity to morphine in patients homozygous for the mutation33. The potential role of 
this interaction network in G protein coupling is supported by the preponderance of basic 
residues (arginine and lysine) at this position in most Gi coupled receptors, whereas Gs-
coupled receptors employ alternative residues (Extended Data Table 2).
A further group of contacts occurs between P17234.50 and V17334.51 of μOR and a 
hydrophobic patch on Gαi comprised of residues F336, I343, I344, and T340 on the α5 
helix and L194 on the β2- β3 loop (Fig. 4b, d). In the GDP bound state, these α5 helix 
residues are buried by the adjacent β2 and β3 loops. Coupling to a receptor involves an 
upward shift of the α5 helix and exposes these residues to form a shallow hydrophobic 
pocket that interacts with μOR V17334.51 in ICL2 (Fig. 4b, d). In the case of Gs, a deeper 
hydrophobic pocket in this region engages the bulky aromatic F13934.51 in ICL2 of the 
β2AR (Fig. 4c, d).
In the μOR, ICL3 stabilizes the interface between receptor and G protein through two sets of 
interactions: one set involves multiple contacts with a hydrophobic patch on the α5 helix of 
Gαi, while another engages the β6 strand of Gαi through a network of charged residues 
(Fig. 5a, b). The hydrophobic interface formed by ICL3 is similar in both the μOR and 
β2AR; in the β2AR, TM5 is helically extended to form a larger hydrophobic interaction 
around nonpolar residues in the α5 helix of Gαs (Fig. 5c, d). While the shorter ICL3 of the 
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μOR does not form a similar helical extension, it nevertheless fulfills the same role. Residues 
V2625.68, M264 and L265 fold back to form a hydrophobic patch that interacts with 
hydrophobic residues on the α5 helix of Gαi (Figure 5a).
The second set of polar contacts involves μOR R263 and a backbone carbonyl to I319 on the 
β6 strand of Gαi (Fig. 5a). Mutations of R263 reduce, but do not abolish, Gi signaling34, 
which is consistent with the potential importance of stabilizing the Gαi β6 strand in the 
observed conformation. A similar interaction is absent in the β2AR-Gs complex (Fig. 5c). 
This additional recognition interface may be necessary for efficient μOR-Gi coupling due to 
the higher affinity for GDP to Gi relative to Gs. Compared to Gs-coupled receptors, 
additional interactions with the β6 strand in Gi-coupled receptors may be required to disrupt 
interactions between the Ras domain and GDP for efficient nucleotide exchange.
The cytosolic ends of μOR TMs 3,5 and 6 further stabilize the nucleotide-free conformation 
of the α5 helix by interacting with highly conserved residues in the distal C-terminus of Gαi 
(Figure 5b). In particular, C351 (−4 position) of Gαi is in close proximity to the cytosolic 
end of μOR TM3. This cysteine residue has previously been identified as the site of pertussis 
toxin-mediated inhibition of Gi/o family proteins by enzymatic ADP-ribosylation35. The 
close apposition of C351 to the μOR cytoplasmic surface highlights how the addition of a 
bulky modification at this position can completely inhibit receptor coupling and nucleotide 
exchange35. In addition to this interaction, μOR residues M2555.61, I2786.33, M2816.36, and 
V2826.37 form a hydrophobic pocket that engages the absolutely conserved Gαi residue 
L353 (−2 position) in the α5 helix. Methionines M2555.61 and M2816.36 have previously 
been observed in NMR experiments to respond to activation by DAMGO36, suggesting that 
this region undergoes conformational changes prior to G protein coupling. Further 
stabilization, however, is likely provided by a hydrogen bond between R2776.32 and the 
backbone carbonyl of L353 (Fig. 5b). Notably, interactions between the C-terminus of the 
α5 helix and the receptor core are entirely different in the in the β2AR-Gs complex (Fig. 5c).
Our findings provide structural insights into the inability of the μOR to couple to Gs, but do 
not explain the mechanism of G protein coupling specificity across all GPCRs. It is possible 
that coupling specificity is determined at an intermediate step in the formation of a GPCR-G 
protein complex, such as the initial interactions between the GDP-bound G protein and the 
agonist-bound receptor. Recent single molecule fluorescence studies provide evidence for a 
transient intermediate complex between GDP-bound Gs and the β2AR that is associated with 
a smaller outward movement of TM637. Previous studies suggest that amino acids C-
terminal to helix 8 confer coupling specificity for Gq in the M3 muscarinic receptor 
(M3R)38. Given that there are no interactions between the C-terminus of the β2AR or μOR 
with their respective G proteins in the nucleotide-free complexes, we postulate that 
engagement of Gq and the M3R C-terminus may occur at an earlier stage in complex 
formation. Thus, the nucleotide-free GPCR-G protein complex may be preceded by one or 
more GDP-bound intermediates characterized by dynamic low affinity interactions with the 
receptor. Such initial encounter complexes may have larger energetic differences for 
interactions with various G protein subtypes than the nucleotide-free state, and would 
thereby contribute more critically to coupling specificity. The transient nature of such 
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interactions, however, currently poses challenges for structure determination by both 
crystallography and cryo-EM.
METHODS
Online Methods
No statistical methods were used to predetermine sample size. The experiments were not 
randomized and the investigators were not blinded to allocation during experiments and 
outcome assessment.
Purification of μ-opioid receptor
These studies utilized a previously described mouse μOR construct with cleavable amino 
and carboxy terminal domains12. Briefly, the receptor was expressed in Spodoptera 
frugiperda Sf9 insect cells using the baculovirus method (Expression Systems), extracted 
from insect cell membranes with n-dodecyl-β-D-maltoside (DDM, Anatrace), and purified 
by nickel-chelating sepharose chromatography. The Ni-NTA eluate was loaded onto M1 
anti-FLAG immunoaffinity resin and washed with progressively lower concentrations of the 
antagonist naloxone. The μOR was then eluted in a buffer consisting of 20 mM Hepes pH 
7.5, 100 mM NaCl, 0.1% DDM, 0.01% cholesterol hemisuccinate (CHS) supplemented with 
50 nM naloxone, FLAG peptide and 5 mM EDTA. The monomeric fraction was purified by 
size exclusion chromatography on a Superdex 200 10/300 gel filtration column (GE) in 20 
mM Hepes pH 7.5, 100 mM NaCl, 0.1% DDM, 0.01% CHS, and 1 μM DAMGO. A further 
2-fold molar excess of DAMGO was added to the preparation and the resulting agonist-
bound μOR preparation was concentrated to ~100 μM.
Expression and purification of heterotrimeric Gi
Heterotrimeric Gi was expressed and purified as previously described24. Briefly, 
Trichuplusia ni Hi5 insect cells were coinfected with two viruses, one encoding the wild-
type human Gαi subunit and another encoding the wild-type human β1γ2 subunits with an 
octahistidine tag inserted at the amino terminus of the β1 subunit. Cultures were harvested 
48 hours post infection. Cells were lysed in hypotonic buffer and lipid-modified 
heterotrimeric Gi was extracted in a buffer containing 1% sodium cholate. The soluble 
fraction was purified using Ni-NTA chromatography, and the detergent was exchanged from 
cholate to DDM on column. After elution, the protein was dialyzed against a buffer 
containing 20 mM Hepes pH 7.5, 100 mM NaCl, 0.015% DDM, 100 μM TCEP, 10 μM 
GDP, and concentrated to ~20 mg/mL for further complexing with the μOR.
Generation of scFv16
6–8 week old female Balb/c mice were immunized with a purified rhodopsin-Gi complex39. 
Hybridoma cells were prepared using splenocytes of immunized mice using standard 
methods in combination with PAI myeloma cells. Clones that showed a positive reaction to 
purified rhodopsin(N2C/D282C/M257Y)/Gi1 complex in an ELISA assay and by 
immunoprecipitation were further characterized as monoclonal antibodies or Fab fragments. 
Fab-16 was selected from the initial pool of clones because it prevented dissociation of the 
rhodopsin (N2C/D282C/M257Y)/Gi1 complex by GTPγS, and therefore acted as a 
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stabilizing chaperone in the same manner as Nb35 for Gs. The full sequence of constructs 
used is listed in Supplemental Figure 1. All animal studies were performed at Roche 
Innovation Center Basel according to ethical guidelines. All cell lines were obtained from 
manufacturer and tested for contamination.
A carboxy-terminal hexahistidine-tagged single chain construct of Fab16 (scFv16) was 
cloned into a modified pVL1392 vector containing a GP67 secretion signal immediately 
prior to the amino terminus of the scFv, expressed in secreted form from Trichuplusia ni Hi5 
insect cells using the baculoviral method, and purified by Ni-NTA chromatography. 
Supernatant from baculoviral infected cells was pH balanced by addition of Tris pH 8.0. 
Chelating agents were quenched by addition of 1 mM nickel chloride and 5 mM calcium 
chloride and incubation with stirring for 1 hr at 25 °C. Resulting precipitates were removed 
by centrifugation and the supernatant was loaded onto Ni-NTA resin. The column was 
washed with 20 mM Hepes pH 7.5, 500 mM NaCl, and 10 mM imidazole followed by a low 
salt wash comprised of the same buffer substituted with 100 mM NaCl. Following elution 
with the same buffer supplemented with 250 mM imidazole, the carboxy-terminal 
hexahistidine tag was cleaved by incubation with human rhinovirus 3C protease, and the 
protein was dialyzed into a buffer consisting of 20mM Hepes pH 7.5 and 100 mM NaCl. 
Cleaved scFv16 was further purified by reloading over Ni-NTA resin. The flow-through was 
collected and purified over gel filtration chromatography using a Superdex 200 16/60 
column. Monomeric fractions were pooled, concentrated, and flash frozen in liquid nitrogen 
until further use.
Formation and purification of the μOR-Gi-scFv16 complex
Purified DAMGO-bound μOR was mixed with a 1.2 molar excess of Gi heterotrimer. The 
coupling reaction was allowed to proceed at 24 °C for 1 hour and was followed by addition 
of apyrase to catalyze hydrolysis of unbound GDP, which destabilizes the nucleotide-free 
complex40. After one more hour at 25 °C, a 4-fold volume of 20 mM Hepes pH 7.5, 100 
mM NaCl, 1% lauryl maltose neopentyl glycol (L-MNG), 0.1% CHS was added to the 
complexing reaction to initiate detergent exchange. After one hour incubation at 25 °C to 
allow micelle exchange, 1 mM MnCl2 and lambda phosphatase (New England Biolabs) were 
added to dephosphorylate the preparation. This reaction was further incubated at 4 °C for 2 
hours. To remove excess G protein and residual DDM, the complexing mixture was purified 
by M1 anti-FLAG affinity chromatography. Bound complex was first washed in a buffer 
containing 1% L-MNG, followed by washes in gradually decreasing L-MNG concentrations. 
The complex was then eluted in 20mM Hepes pH 7.5, 100mM NaCl, 0.01% MNG/0.001% 
CHS, 300 nM DAMGO, 5 mM EDTA, and FLAG peptide. The eluted complex was 
supplemented with 100 μM TCEP to provide a reducing environment. The tobacco etch 
virus (TEV) protease and human rhinovirus 3C protease were added to cleave the flexible 
μOR amino- and carboxy- termini. Finally, a 1.2 molar excess of scFv16 was added to the 
preparation. Once cleavage of the termini was confirmed by SDS-PAGE, the μOR-Gi-
scFv16 complex was purified by size exclusion chromatography on a Superdex 200 10/300 
column in 20mM Hepes pH 7.5, 100mM NaCl, 300 nM DAMGO, 0.00075% MNG and 
000025% GDN. Peak fractions were concentrated to ~7 mg/mL for electron microscopy 
studies.
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Cryo-electron microscopy of μOR-Gi-scFv16 complex
3.0 μL of purified μOR-Gi-scFv16 complex was applied to glow-discharged 200 mesh grids 
(Quantifoil R1.2/1.3) and subsequently vitrified using a Vitrobot Mark IV (Thermo Fischer 
Scientific). Cryo-EM imaging was performed on a Titan Krios operated at 300 kV at a 
nominal magnification of 130,000x using a Gatan K2 Summit direct electron camera in 
counted mode, corresponding to a pixel size of 1.04 Å. A total of 2642 image stacks were 
obtained with a defocus range of −0.8 to −2.6 μm. Each stack movie was recorded for a total 
of 8 seconds with 0.1s per frame. The dose rate was 5 e/Å2/s, resulting in an accumulated 
dose of 40 electrons per Å2.
Dose fractionated image stacks were subjected to beam-induced motion correction using 
MotionCor241. A sum of all frames, filtered according to exposure dose, in each image stack 
was used for further processing. CTF parameters for each micrograph were determined by 
Gctf v1.0642. Particle selection, two-dimensional and three-dimensional classification, and 
3D reconstruction were performed using RELION2.143, apart from the last round of local 
refinement and reconstruction that was performed with Frealign44. Semi-automated selected 
893,426 particle projections were subjected to reference-free two-dimensional classification 
and averaging using a binned data set with a pixel size of 2.08 Å. 379,373 particles 
belonging to well-defined averages were subjected to further processing. An ab initio map 
generated by VIPER45 was used as initial reference model for maximum-likelihood-based 
three-dimensional classification, which, however did not produce classes with notable 
differences. Thus, all 379,373 particle projections were subjected to 3D refinement, 
producing a map at 4.3 Å resolution. The dataset was further reduced by removing particle 
projections from micrographs with resolution lower than 4.5 Å, resulting in a data set of 
359,406 particles that were subjected to refinement and reconstruction after subtracting 
densities for the mobile Gα α-helical domain and the detergent micelle11. Particle 
projection assignments from RELION were imported into Frealign46 for a final round of 
local refinement and reconstruction. To prevent overfitting, the resolution limit for every 
alignment iteration never exceeded the 0.9 value of the Frealign calculated FSC. The map 
was further improved map after additionally subtracting densities corresponding to the ScFv 
from the raw particle projections11. The indicated resolution, using Phenix “gold standard” 
FSC47, of the final reconstruction is 3.5 Å and 3.6 Å at FSC 0.143 for the ScFv subtracted 
map and the ScFv including map, respectively. Local resolution was determined using the 
Bsoft package48 with unfiltered half-maps as input.
Model Building and Refinement
The building of a full atomic model for the μOR-Gi complex was aided by the quality and 
resolution of our map, as well as the existence of high-resolution crystal structures of each of 
the components that make up the complex. A composite model was formed by rigid body 
fitting of the active-state μOR (PDB ID: 5C1M)12 with nanobody removed, as well as the 
Ras domain and βγ subunits of GDP-bound Gi (PDB ID: 1GP2)23. The α5 helix of Gαi was 
removed and manually fit to the density, and the final 8 residues missing from the extreme 
C-terminus of the 1GP2 structure were manually built in coot49. This starting model was 
then subjected to iterative rounds of automated refinement in Rosetta50 and Phenix real 
space refine47, and manual building in Coot49. In the regions of the model for which side 
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chain density was too weak to unambiguously assign a conformation, we stubbed residues to 
their C βposition, while preserving sequence information (Supplemental Figure 2,3). The 
final model was visually inspected for general fit to the map, and geometry was further 
evaluated using Molprobity51 as part of the Phenix suite of software. Initial restraints for 
DAMGO were generated using the PRODRG server52. To further refine the pose of 
DAMGO, we chose a pose from molecular dynamics simulation consistent with our map 
and then performed a refinement using Phenix. This involved manually editing the residue 
and atom names from a CHARMM parameter file to match the 3-letter codes and atom 
names from the rcsb. In particular, DAL for D-alanine, MEA for N-methyl phenylalanine, 
and ETA for Gly-ol C terminus. Additional, custom, restraints were generated to keep 
planarity of the final peptide bond between MEA and ETA as a supplement to the natural 
library of phenix amino acid restraints. Model overfitting was evaluated through its 
refinement against one cryo-EM half map after randomly displacing all atoms by 0.2 Å. FSC 
curves were calculated between the resulting model and the half map used for refinement 
(green curve, Extended Data Fig. 2b, c), as well as between the resulting model and the other 
half map for cross- validation (blue curve, Extended Data Fig. 2b, c), and also against the 
full map (red curve, Extended Data Fig. 2b, c). The final refinement statistics for both 
models are provided in Extended Data Table 1.
System setup for molecular dynamics simulations
Molecular dynamics simulations were initiated from an earlier refinement of the structure 
reported in this study after removing the G protein and ScFv fragment. Prior to beginning 
simulations, Schrödinger Glide53 was used to relax DAMGO to an energetically favorable 
conformation. The initial DAMGO pose is depicted in Extended Data Figure 3. We 
performed five independent simulations, for each of which initial atom velocities were 
assigned randomly and independently. Prime (Schrödinger, Inc.) was used to model missing 
side chains, and neutral acetyl and methylamide groups were added to cap protein termini. 
Titratable residues remained in their dominant protonation state at pH 7, as determined using 
PropKa, except for D2.50 and D3.49 which were protonated. Our simulations incorporated the 
waters from the 5C1M crystal structure.
The prepared protein structures were aligned to the Orientation of Proteins in Membranes 
(OPM) structure for PDB entry 5C1M54. The aligned structures were then inserted into a 
pre-equilibrated palmitoyl-oleoyl-phosphatidylcholine (POPC) bilayer using Dabble, a 
simulation preparation software55. Sodium and chloride ions were added to neutralize each 
system at a concentration of approximately 150 mM. Bilayer dimensions were chosen to 
maintain at least a 30 Å buffer between protein images in the x-y plane and a 20 Å buffer 
between protein images in the z direction. Final system dimensions were approximately 80 × 
75 × 90 Å3. Simulation times for each replicate were approximately 1 μs.
Molecular dynamics simulation protocols
We used the CHARMM36m force field for proteins, lipids, and ions and the TIP3P model 
for waters56–60. Parameters for the non-canonical residues in DAMGO were determined by 
analogy to N-methyl glycine for assigning N-methyl parameters to N-methyl phenylalanine 
(residue 4) and by analogy to serine to assign parameters to the Gly-ol capping group 
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(residue 5). CMAP terms for D-alanine were inverted from those for L-Alanine to account 
for the inverted chirality of the residue.
We performed the simulations using the Compute Unified Device Architecture (CUDA) 
version of Particle-Mesh Ewald Molecular Dynamics (PMEMD) in AMBER on one or two 
graphical processing units (GPUs)61. Simulations were performed using the AMBER1662 
software. Three rounds of minimization were performed, each consisting of 500 iterations of 
steepest descent minimization, followed by 500 iterations of conjugate gradient descent 
minimization, with harmonic restraints of 10.0, 5.0, and 1.0∙kcal∙mol−1∙Å−2 placed on the 
protein and lipids. Systems were heated from 0K to 100K in the NVT ensemble over 12.5 ps 
and then from 100K to 310K in the NPT ensemble over 125 ps, using 10.0∙kcal∙mol−1∙Å−2 
harmonic restraints applied to lipid and protein heavy atoms. Systems were then equilibrated 
at 310 K in the NPT ensemble at 1 bar, with harmonic restraints on all protein heavy atoms 
tapered off by 1.0 kcal∙mol−1∙Å−2 starting at 5.0∙kcal∙mol−1∙Å−2 in a stepwise fashion every 
2 ns for 10 ns and then by 0.1 kcal∙mol−1∙Å−2 in a stepwise fashion every 2 ns for 20 ns. 
Production simulations were performed in the NPT ensemble at 310K and 1 bar, using a 
Langevin thermostat for temperature coupling and a Monte Carlo barostat for pressure 
coupling. These simulations used a 4 fs time step with hydrogen mass repartitioning63. Bond 
lengths to hydrogen atoms were constrained using SHAKE. Simulations used periodic 
boundary conditions. Non-bonded interactions were cut off at 9.0 Å, and long-range 
electrostatic interactions were computed using Particle Mesh Ewald (PME) with an Ewald 
coefficient of approximately 0.31 Å and an interpolation order of 4. The FFT grid size was 
chosen such that the width of a grid cell was approximately 1 Å.
During production simulations, all residues within 5 Å of the G protein interface were 
restrained to the initial structure using 5.0 kcal∙mol−1∙Å−2 harmonic restraints applied to 
non-hydrogen atoms. Using such restraints reduces the overall system size, enabling more 
simulation, while ensuring that the receptor maintains an active conformation throughout the 
simulation.
Analysis protocols for MD simulation
Trajectory snapshots were saved every 200 ps during production simulations. The 
AmberTools17 CPPTRAJ package was used to reimage and center trajectories64. 
Simulations were visualized and analyzed using Visual Molecular Dynamics (VMD)65. In 
two simulations, DAMGO was trapped in an unstable binding pose, wherein the water-
mediated interaction between the DAMGO Tyr residue and His297 failed to form during 
equilibration, and instead a direct hydrogen bond between these residues was formed. Our 
analysis is based on the other three simulations, in which DAMGO’s pose was consistent 
with the EM density. Water occupancy maps were generated using AmberTools17 
GIST66,67. Frames from every 1 ns of simulation, excluding the first 400 ns, aligned to the 
initial structure, were used as input. The grid size was set to 0.25 Å. The resulting map was 
smoothed using a Gaussian filter with a standard deviation of 2 grid cells.
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Extended Data
Extended Data Figure 1. scFv binding characteristics
scFv 16 does not perturb the interfaces between Gα and Gβ at a) its binding epitope or b) 
the Switch II region located ~40A away. Our structure is colored by chain, while the 
structure of GDP-bound Gi1 heterotrimer (PDB 1GP2) is colored grey. c) In the nucleotide-
free state, there is a ~7˚ rotation of G βγ relative to the Gαs Switch II domain when 
compared to the GDP-bound form. This rotated conformation is similar to that observed in 
nucleotide-free Gs coupled to the β2AR (PDB ID 3SN6) as shown in panel d).
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Extended Data Figure 2. Cryo-EM data processing
a, Representative cryo-EM micrograph of the μOR-Gi complex. Scale bar, 20nm.
b, Representative two-dimensional averages showing distinct secondary structure features 
from different views of the complex.
c, Flow chart of cryo-EM data processing. The unmasked map in the middle of the chart has 
been colored by subunit. The inset shows the fit of the crystal structure of the α-helical 
domain in the corresponding density of the unmasked reconstruction. Three-dimensional 
density maps colored according to local resolution.
d, “Gold standard” Fourier shell correlation (FSC) curves from Phenix indicates overall 
nominal resolutions of 3.5 Å and 3.6 Å using the FSC=0.143 criterion for the scFv-
subtracted map (green curve) and scFv-retained maps (purple curve), respectively.
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Extended Data Figure 3. Cryo-EM map vs. refined structure
a) EM density map (scFv subtracted) and model are shown for all seven transmembrane α-
helices of the μOR, DAMGO, and Gα helices α5 and αN.
b,c) Cross-validation of model to EM density map. The model was refined against one half 
map after displacement of atoms by 0.2A, and FSC curves were calculated between this 
model and the final cryo-EM map (full dataset, black), of the outcome of model refinement 
with a half map versus the same map (red), and of the outcome of model refinement with a 
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half map versus the other half map (green). The results of the scFv-retained model vs. map 
and of scFv subtracted model vs. map are shown in b) and c), respectively.
Extended Data Figure 4. Selected cryo-EM densities of μOR-Gi Complex
Cryo-EM density (displayed as mesh) surrounding residues involved in a) DAMGO binding, 
b) μOR-Gαi interaction around ICL2, c) ICL3, and d) cytoplasmic ends of the μOR 
transmembrane helices. These figures accompany the models shown in figures 1e, 4b, 5a, 
and 5b respectively.
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Extended Data Figure 5. Stability of DAMGO in MD Simulations
a. Over the course of MD simulations, the positions of the first 4 residues of DAMGO do not 
significantly change, while the 5th residue (Gly-ol) shows significant variability in position. 
Frames from the first and last 100 ns are shown with an intermediate to highlight both the 
relative stability of the first 4 amino acids, as well as the flexibility of the fifth. Arrows show 
the extent of motion in the N- and C-terminal residues over the course of simulation. Cryo-
EM density for DAMGO is shown as mesh.
b. Root mean standard deviations (RMSDs) from the modeled pose of DAMGO to the pose 
during MD simulations. The RMSD calculations include heavy atoms on the peptide 
backbone. Data from three independent simulations are plotted. The RMSDs for residues 1 
to 4 (black) and the C-terminal Gly-ol (blue) are plotted separately to highlight their stability 
and mobility, respectfully.
Koehl et al. Page 17
Nature. Author manuscript; available in PMC 2019 January 03.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Extended Data Figure 6. Water occupancy in orthosteric binding site
Left panel, water occupancy in MD simulations of DAMGO-bound μOR overlaid with a 
representative conformation from MD simulations. ‘Occupancy relative to bulk solvent’ is 
the ratio of the rate at which water is observed in a given volume to the rate at which water is 
expected to be observed in an equivalent volume in the bulk solvent. For example, blue 
regions (occupancy ratio = 2) are occupied by water twice as often as an equivalent region in 
the bulk solvent. Right panel, crystallographic waters in the BU72-bound μOR binding 
pocket (PDB ID: 5C1M). Waters are shown as black spheres, BU72 is shown as yellow 
sticks, and hydrogen bonds are shown as dashed lines.
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Extended Data Figure 7. Comparison of the C-termini of Gαs and Gαi
The C-terminus of Gαs is bulkier than that of Gαi due to substitution of small amino acids C 
(−4 position) and G (−3 position) in Gαi to Y and E respectively in Gαs. This leads to steric 
clashes with TMs 3 and 7 of the μOR.
Top - ribbon view of μOR (green) with WT Gαi (gold, left) and a Gαis model (right) created 
by substituting C and G for Y and E based on the β2AR-Gs crystal structure. Substituted 
positions are colored in light purple. The −4 to −2 positions have their side chains shown as 
spheres, and the rest as a ribbon.
Bottom - space filling view of the μOR showing the steric clashes that result from these 
substitutions.
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Extended Data Figure 8. Comparison of Gai C terminal peptide binding modes
Side (top half), and cytoplasmic (bottom half) views of a) the μOR (green) with the last 11 
residues of Gαi (gold) alone, b) compared to the β2AR(orange) with the last 11 residues of 
Gαs (light purple) (PDB ID 3SN6), or c) compared to MetaII Rhodopsin (pink) in complex 
with an 11 residue Gtransducin (Gt) C-terminal peptide (dark purple) (PDB ID 3PQR). The 
mOR-Gi complex aligns best with the MetaII-Gt complex both in terms of TM6 
displacement as well as position of the α5 peptide.
Extended Data Table 1
Cryo-EM data collection, refinement and validation statistics
μOR-Gi Complex (EMDB-xxxx) (PDB 
xxxx)
μOR-Gi-scFvl6 Complex (EMDB-
yyyy) (PDB yyyy)
Data collection and processing
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μOR-Gi Complex (EMDB-xxxx) (PDB 
xxxx)
μOR-Gi-scFvl6 Complex (EMDB-
yyyy) (PDB yyyy)
Magnification 48,076 48,076
Voltage (kV) 300 300
Electron exposure (e–/Å2) 40 40
Defocus range (μm) −0.8 ~ −2.6 −0.8 ~ −2.6
Pixel size (Å) 1.04 1.04
Symmetry imposed C1 C1
Initial particle images (no.) 893,426 893,426
Final particle images (no.) 359,406 359,406
Map resolution (Å) 3.5 Å 3.6 Å
 FSC threshold (0.143) (0.143)
Map resolution range (Å) 3.3-4.5 3.3-4.5
Refinement
Initial model used (PDB code) 5C1M
1GP2
5C1M
1GP2
Model resolution (Å) 3.5 3.6
Model resolution range (Å) 3.3-4.5 3.3-4.5
Map sharpening B factor (Å2) Pre −90, post −60 Pre −90, post −60
Model composition
 Non-hydrogen atoms 6986 8731
 Protein residues 886 residues (6949 atoms) 1119 residues (8694 atoms)
 Ligands 1 (37 atoms) 1 (37 atoms)
B factors (Å2)
 Protein 33.23 60.55
 Ligand 31.27 79.99
R.m.s. deviations
 Bond lengths (Å) 0.007 0.007
 Bond angles (°) 1.311 1.015
Validation
 MolProbity score 1.89 1.89
 Clashscore 7.02 8.16
 Poor rotamers (%) 0.72 0.92
Ramachandran plot
 Favored (%) 91.54 92.93
 Allowed (%) 8.35 6.98
 Disallowed (%) 0.11% 0.09%
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Extended Data Table 2
Sequence alignment of residues that form the interaction interface between μOR and Gi. 
Receptors from different branches of the GPCR family with different coupling specificity 
were selected for analysis. Sequences and alignment were performed using GPCRDB 
(gpcrdb.org)
Coupling Branch
mOR Residue T103 V169 P172 V173 D177 R179 T180 M255 K271 R277 I278
2.39 3.54 34.50 34.51 34.55 34.57 4.38 5.61 6.26 6.32 6.33
[Human] 5-HT1A receptor Gi α A I P I N R T I A K T
[Human] 5-HT1B receptor Gi α A I A V A R T I M K A
[Human] M2 receptor Gi α N V P L V R T I P K V
[Human] M4 receptor Gi α N V P L A R T I M K V
[Human] alpha2A-adrenoceptor Gi α Q I A I L R T I R R F
[Human] FPR1 Gi γ T V P V N R T I – R P
[Human] FPR2/ALX Gi γ T V P V N R T I – R P
[Human] GAL1 receptor Gi γ T I S R S R V V – K T
[Human] GAL3 receptor Gi γ T V P L A R T T R R A
[Human] &delta; receptor Gi γ T V P V D R T M K R I
[Human] &kappa; receptor Gi γ T V P V D R T M K R I
[Human] &mu; receptor Gi γ T V P V D R T M K R I
[Human] NOP receptor Gi γ T I P I D R T M K R I
[Human] SST1 receptor Gi γ T V P I R R R I R K I
[Human] SST2 receptor Gi γ T V P I K R R I R K V
[Human] SST3 receptor Gi γ T V P T R R T I R R V
[Human] SST4 receptor Gi γ T V P L T R R I R K I
[Human] SST5 receptor Gi γ T V P L R R R I – K V
[Human] CCR1 Gi γ T I A V R R T I – K A
[Human] CCR4 Gi γ T I A V R R T I – K A
[Human] CXCR4 Gi γ T I A T R R K I – K A
[Human] A1 receptor Gi α T V P L M V T V Y K I
[Human] beta1-adrenoceptor Gs α T I P F S L T V V K A
[Human] beta2-adrenoceptor Gs α T I P F S L T V F K A
[Human] MC1 receptor Gs α M I A L S V T G – K G
[Human] MC2 receptor Gs α M I A L S V T K – K G
[Human] MC4 receptor Gs α M I A L N M T R – K G
[Human] A2A receptor Gs α T I P L G V T I T H A
[Human] H2 receptor Gs α T V P L V V T I A K A
[Human] TA1 receptor Gs α T V P L A M N I S K A
[Human] RXFP1 Gs δ Y I P F R – G M Q I L
[Human] RXFP2 Gs δ H I P F R – G M C A V
[Human] V2 receptor Gs β I I P M R G S I V K T
[Human] 5-HT2A receptor Gq α T I P I R N S T S K A
[Human] 5-HT2B receptor Gq α T I P I Q N S T T R A
[Human] M1 receptor Gq α N V P L A R T I S K A
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Coupling Branch
[Human] M3 receptor Gq α N I P L A R T I S K A
[Human] M5 receptor Gq α N I P L A R T I V K A
[Human] alpha1A-adrenoceptor Gq α T V P L T V T V K K A
[Human] GAL2 receptor Gq γ T I P L E R T T A K V
[Human] OX1 receptor Gq β T I P L – – T I Q K T
[Human] OX2 receptor Gq β T I P L – – T I Q K T
[Human] NK1 receptor Gq β T I – – – – S V Q K V
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Figure 1. Cryo-EM structure of the μOR-Gi complex
a, Orthogonal views of the cryo-EM density map of the μOR-Gi heterotrimer complex 
colored by subunit (μOR in green, DAMGO in orange, G⍺s Ras-like domain in gold, Gβ in 
cyan, Gγ in purple). b, Model of the μOR-Gi complex in the same views and color scheme 
as shown in a. c, Residues that line the μOR orthosteric binding pocket are shown as sticks 
for the μOR-Gi complex (green) and the μOR-Nb39 complex (PDB 5C1M; blue). The 
binding pocket residues of DAMGO and BU-72 occupied μOR show nearly identical 
conformations, despite differences in ligand structure. d, Comparison of BU-72 (yellow 
carbons) in the orthosteric pocket of the μOR-Nb39 complex (blue) with DAMGO (orange 
carbons) in the orthosteric pocket of the μOR-Gi complex (green). e, view of DAMGO in the 
orthosteric binding pocket with critical residues shown. f, A frame from every 100 ns of a 1 
μs MD simulation (yellow for t = 0 fading to red for t = 1 μs) shows that the first 4 residues 
of DAMGO (bottom) are stable, whereas the C-terminal Gly-ol (top) is dynamic but 
frequently returns to the modeled pose.
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Figure 2. Structural changes in the μOR stabilized by nucleotide-free Gi
a, Comparison of inactive μOR (brown) and the Gi stabilized active state of μOR (green). b, 
Comparison of Nb39 and Gi stabilized active states of the μOR (blue and green, 
respectively). The structures are nearly identical except for a slight shift of TM6 towards 
TM7 in the Gi -bound state. c, Residues important for activation of the μOR show nearly 
identical conformations despite the difference in ligands. d, Comparison of Gs-stabilized 
β2AR (orange) and Gi-stabilized μOR (green). While most transmembrane helices align well 
between the two receptors, TM6 is kinked further outward by 9Å in the β2AR. Distance 
calculated between Cα of residue 6.29 (Ballesteros-Weinstein numbering) in TM6.
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Figure 3. Changes in Gi upon coupling to the μOR
a, b, Comparison of GDP-bound Gαi (PDB 1GP2, grey) and nucleotide-free Gαi from the 
μOR-Gi complex (gold). GDP is shown as blue spheres in panel a and sticks in panel b. The 
primary differences between these two structures are the opening and outward movement of 
the alpha helical domain (AHD), and an upward shift of the α5 helix by 6Å to engage the 
receptor core. The α-carbons of the TCAT motif are represented as spheres in panel b. The 
TCAT motif coordinates the guanosine base of GDP. The upward shift of the α5 helix and 
repositioning of the TCAT motif leads to nucleotide release. c, d, e, The interface between 
the α1 helix and the N-terminal end of the α5 helix and TCAT motif for GDP-bound Gαi 
(c), nucleotide free Gαi (d), and nucleotide free Gs from the β2AR -Gs complex (e). The 
upward movement of the α5 helix disrupts the interaction between the α1 and α5 helices 
leading to changes in the P-loop that coordinates the phosphates of GDP.
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Figure 4. Comparison of the receptor-G protein binding interfaces of the μOR-Gi and β2AR-Gs 
complexes
a, Comparison of the conformation of the α5 helix of Gα and receptor TM6 in β2AR-Gs and 
μOR-Gi complexes after alignment on the receptor. b, Interactions between ICL2 of the μOR 
(green) and Gαi (gold). Asp 350 of Gαi is depicted with narrow lines to indicate uncertainty 
in its conformation due to poor cryo-EM density for its side chain. c, Interactions between 
ICL2 of the β2AR (orange) and Gαs (blue). d, Surface view of the hydrophobic pockets in 
Gαi (top panel) and Gαs (bottom panel) that interact with a non-polar amino acid in ICL2 of 
the μOR and β2AR, respectively.
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Figure 5. Comparison of the receptor-G protein binding interfaces of the μOR-Gi and β2AR-Gs 
complexes
Top panels show interactions between ICL3 of μOR and Gαi (a) and between the cytosolic 
ends of TMs 3,5,6, of the μOR and the α5 helix of Gi (b). Asp 350 of Gαi is depicted with 
narrow lines to indicate uncertainty in its position due to poor cryo-EM density for its side 
chain. Bottom panels show these same interfaces between β2AR and Gs (c,d).
Koehl et al. Page 31
Nature. Author manuscript; available in PMC 2019 January 03.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
